Recent guidelines for diagnostic and therapeutic management of accidentally detected adrenal tumours (incidentaloma) in adults
Abstract
At the end of 2023, the European Journal of Endocrinology published the latest guidelines of the European Society of Endocrinology (ESE) on the management of accidentally detected adrenal tumours (incidentalomas) in adults. Comparing them with the previous version of the ESE recommendations from 2016, a tendency towards far-reaching individualisation of the therapeutic and diagnostic approach in patients with adrenal incidentaloma can be seen — it is reflected by changes in the initial assessment of the malignancy of the lesion, in the scope of the proposed hormonal assessment, and qualification for surgery.
The latest version of the guidelines includes 9 completely new recommendations, and 5 more recommendations have been significantly changed. Among the most important changes, the introduction of the term “mild autonomous cortisol secretion” (MACS) instead of the previously used term “autonomous cortisol secretion (ACS)” along with more precise recommendations regarding its management should be emphasised. An important novelty is also the modification of the criteria for benign adrenal adenoma, which does not require further imaging observation — due to the results of recent clinical studies, the authors have removed the criteria of size below 4 cm from the definition. Among others, the guidelines also encourage more proactive surgical treatment of indeterminate adrenal incidentaloma in people < 40 years of age and pregnant women. The authors of the recommendations repeatedly accentuate the importance of a multidisciplinary approach in making decisions regarding further management of patients with an unspecified adrenal tumour.
Despite a few significant differences compared to the previous version of guidelines, the authors emphasise the presence of gaps in the current scientific evidence, which would not allow for the formulation of more unambiguous recommendations. The need to optimise ordered diagnostic tests, which generate additional socio-economic burdens without negative impact on patients’ health, is also an important aspect of the latest guidelines.
Keywords: adrenal incidentalomaadrenal tumouradrenal adenoma
References
- NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens State Sci Statements. 2002; 19(2): 1–25.
- Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009; 15(Suppl 1): 1–20.
- Kapoor A, Morris T, Rebello R. Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J. 2011; 5(4): 241–247.
- Terzolo M, Stigliano A, Chiodini I, et al. Italian Association of Clinical Endocrinologists. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011; 164(6): 851–870.
- Lee JM, Kim MK, Ko SH, et al. Korean Endocrine Society, Committee for Clinical Practice Guidelines. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab (Seoul). 2017; 32(2): 200–218.
- Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016; 172(2): G1–G34.
- Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004; 25(2): 309–340.
- Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003; 138(5): 424–429.
- Sherlock M, Scarsbrook A, Abbas A, et al. Adrenal Incidentaloma. Endocr Rev. 2020; 41(6): 775–820.
- Ebbehoj A, Li D, Kaur RJ, et al. Epidemiology of adrenal tumours in Olmsted county, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. 2020; 8(11): 894–902.
- Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003; 149(4): 273–285.
- Barzon L, Scaroni C, Sonino N, et al. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab. 1999; 84(2): 520–526.
- Bernini GP, Moretti A, Oriandini C, et al. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer. 2005; 92(6): 1104–1109.
- Fagour C, Bardet S, Rohmer V, et al. Usefulness of adrenal scintig- raphy in the follow-up of adrenocortical incidentalomas: a pro- spective multicenter study. Eur J Endocrinol. 2009; 160(2): 257–26.
- Libe R, Dall’Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal in- cidentalomas. Eur J Endocrinol. 2002; 147(4): 489–494.
- Deutschbein T, Reimondo G, Di Dalmazi G, et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol. 2022; 10(7): 499–508.
- Kjellbom A, Lindgren O, Puvaneswaralingam S, et al. Association Between Mortality and Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas : A Cohort Study. Ann Intern Med. 2021; 174(8): 1041–1049.
- Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol. 2012; 166(4): 669–677.
- Sbardella E, Minnetti M, D'Aluisio D, et al. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. Eur J Endocrinol. 2018; 178(5): 501–511.
- Chiodini I, Guglielmi G, Battista V, et al. Spinal volumetric bone mineral density and vertebral fractures in female patients with ad- renal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab. 2004; 89(5): 2237–2241.
- Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hyper- cortisolism: an Italian multicenter study. J Clin Endocrinol Metab. 2009; 94(9): 3207–3214.
- Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovas- cular outcomes: a large cross-sectional study. Eur J Endocrinol. 2012; 166(4): 669–677.
- Eller-Vainicher C, Morelli V, Ulivieri FM, et al. Bone quality, as measured by trabecular bone score in patients with adrenal inci- dentalomas with and without subclinical hypercortisolism. J Bone Miner Res. 2012; 27(10): 2223–2230.
- Deutschbein T, Reimondo G, Dalmazi GDi, et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol . 2022; 10(7): 499–508.
- Kjellbom A, Lindgren O, Danielsson M, et al. Association Between Mortality and Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas : A Cohort Study. Ann Intern Med. 2021; 174(8): 1041–1049.
- Gruber L, Young WF, Bancos I, et al. Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. J Clin Endocrinol Metab. 2019; 104(5): 1386–1393.
- Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multi-center study. Eur J Endocrinol. 2018; 178(5): 431–437.
- Canu L, Van Hemert JAW, Kerstens M, et al. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. J Clin Endocrinol Metab. 2019; 104(2): 312–318.
- Cooper AB, Habra MA, Grubbs EG, et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surg Endosc. 2013; 27(11): 4026–4032.
- Mihai R, Donatini G, Vidal O, et al. Volume-outcome correlation in adrenal surgery — an ESES consensus statement. Langenbecks Arch Surg. 2019; 404(7): 795–806.
- Park HS, Roman SA, Sosa JA. Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Arch Surg. 2009; 144(11): 1060–1067.
- Kerkhofs TM, Verhoeven RH, Bonjer HJ, et al. Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013; 169(1): 83–89.
- Elhassan YS, Alahdab F, Prete A, et al. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med. 2019; 171(2): 107–116.
- Collienne M, Timmesfeld N, Bergmann SR, et al. Adrenal incidentaloma and subclinical Cushing’s syndrome: a lon-gitudinal follow-up study by endoscopic ultrasound. Ultraschall Med. 2017; 38(04): 411–419.
- Corwin MT, Chalfant JS, Loehfelm TW, et al. Incidentally Detected Bilateral Adrenal Nodules in Patients Without Cancer: Is Further Workup Necessary? AJR Am J Roentgenol. 2018; 210(4): 780–784.
- Goh Z, Phillips I, Hunt PJ, et al. Three-year follow up of adrenal incidentalomas in a New Zealand centre. Intern Med J. 2020; 50(3): 350–356.
